Acadia reports $484.1M 2021 net sales (+10% YoY); net loss narrows to $167.9M

ACADIA PHARMACEUTICALS INC

2022-FY EPS reported -$1.05 revenue$484,145,000

Q4 2021 net product sales $130.8M (+8% YoY); full-year net sales $484.1M (+10% YoY).
Q4 net loss $43.1M ($0.27/sh) vs. $66.8M ($0.42/sh) in Q4 2020; full-year loss $167.9M ($1.05/sh).
Resubmitted sNDA for pimavanserin in Alzheimer's disease psychosis; Phase 3 Lavender trial of trofinetide in Rett syndrome positive.
FY2022 guidance: NUPLAZID net sales $510-560M; R&D expense $355-375M; SG&A $360-380M.
Cash and investments $520.7M at Dec 31, 2021, down from $632.0M a year earlier.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.